Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Reproducibility of research and preclinical validation: problems and solutions

Abstract

Lack of reproducibility in the scientific and lay literature of many scientific reports is an increasing concern, as are the high rates of failure to validate highly promising preclinical observations in clinical trials. There are many technical reasons why experimental results, particularly in cancer research, cannot be reproduced, including unrecognized variables in the complex experimental model, poor documentation of procedures, selective reporting of the most-positive findings, misinterpretation of technical noise as biological signal and, in the most extreme cases, fabrication of data. We suggest that cognitive biases in research and flaws in the academic incentive system also contribute to the publication of immature results. Recognition of these factors, which are often not discussed, provides additional strategies to improve reproducibility. We suggest that in addition to establishing better standards of data presentation and creating venues for publication of negative results, some changes to the grant submission and funding system could further improve the reproducibility of research findings.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Swift, R. The relationship between health and GDP in OECD countries in the very long run. Health Econ. 20, 306–322 (2011).

    Article  Google Scholar 

  2. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968 (2009).

    Article  CAS  Google Scholar 

  3. Hutchinson, L. & Kirk, R. High drug attrition rates—where are we going wrong? Nat. Rev. Clin. Oncol. 8, 189–190 (2011).

    Article  Google Scholar 

  4. Arrowsmith, J. Trial watch: Phase II failures: 2008–2010. Nat. Rev. Drug Discov. 10, 328–329 (2011).

    Article  CAS  Google Scholar 

  5. Arrowsmith, J. Trial watch: Phase III and submission failures: 2007–2010. Nat. Rev. Drug Discov. 10, 87 (2011).

    Article  CAS  Google Scholar 

  6. Daher, I. N. & Yusuf, S. W. Quantity and quality in medical research. J. Am. Coll. Cardiol. 56, 527–528 (2010).

    Article  Google Scholar 

  7. Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug. Discov. 10, 712 (2011).

    Article  CAS  Google Scholar 

  8. Ioannidis, J. P. et al. Repeatability of published microarray gene expression analyses. Nat. Genet. 41, 149–155 (2009).

    Article  CAS  Google Scholar 

  9. Lehrer, J. The truth wears off: is there something wrong with the scientific method? [online], (2010).

    Google Scholar 

  10. Sarewitz, D. Beware the creeping cracks of bias. Nature 485, 149 (2012).

    Article  CAS  Google Scholar 

  11. Ransohoff, D. F. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5, 142–149 (2005).

    Article  CAS  Google Scholar 

  12. Ioannidis, J. P. Why most published research findings are false. PLoS Med. 2, e124 (2005).

    Article  Google Scholar 

  13. Goodman, S. & Greenland, S. Assessing the unreliability of the medical literature: A response to “Why most published research findings are false”. John Hopkins University, Department of Biostatistics Working Papers [online], (2007).

    Google Scholar 

  14. Ranstam, J. et al. Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control. Clin. Trials 21, 415–427 (2000).

    Article  CAS  Google Scholar 

  15. Buyse, M. et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat. Med. 18, 3435–3451 (1999).

    Article  CAS  Google Scholar 

  16. Landis, S. C. et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187–191 (2012).

    Article  CAS  Google Scholar 

  17. Bagley, C. G. & Ellis, L. M. Drug development: Raise standards for preclinical cancer research. Nature 483, 531–533 (2012).

    Article  Google Scholar 

  18. [No authors listed] Announcement: Reducing our irreproducibility. Nature 496, 398 (2013).

  19. Moses, H. 3rd, Dorsey, E. R., Matheson, D. H. & Their, S. O. The financial anatomy of biomedical research. JAMA 294, 1333–1342 (2005).

    Article  CAS  Google Scholar 

  20. Fanelli, D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS ONE 4, e5738 (2009).

    Article  Google Scholar 

  21. Nickerson, R. S. Confirmation bias: a ubiquitous phenomenon in many guises. Rev. Gen. Psychol. 2, 175–220 (1998).

    Article  Google Scholar 

  22. ERA-NET on Translational Cancer Research (TRANSCAN). First Joint Transnational Call for Proposals (JTC 2011) [online], (2011).

  23. National Institutes of Health. Validation of molecular diagnostics to predict patient outcomes using specimens from multi-site cancer trials [online], (2013).

  24. Contopoulos-Ioannidis, D. G., Ntzani, E. & Ioannidis, J. P. Translation of highly promising basic science research into clinical applications. Am. J. Med. 114, 477–484 (2003).

    Article  Google Scholar 

  25. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

    Article  Google Scholar 

  26. Adams, C. P. & Brantner, V. V. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood) 25, 420–428 (2006).

    Article  Google Scholar 

  27. Science Exchange. Reproducibility initiative [online], (2013).

  28. Darwin, C. in More letters of Charles Darwin Vol. 2 (eds Darwin, F. & Seward, A. C.) 229 (BiblioBazaar, Charleston, SC, 2008).

    Google Scholar 

  29. Andre, F. et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8, 171–176 (2011).

    Article  Google Scholar 

  30. National Institutes of Health. ClinincalTrials.gov [online], (2013).

  31. Prayle, A. P., Hurley, M. N. & Smyth, A. R. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 344, d7373 (2012).

    Article  Google Scholar 

  32. Freedman, D. H. Lies, damned lies, and medical science [online], (2010).

    Google Scholar 

Download references

Acknowledgements

We are grateful for the constructive comments and suggestions of Lisa McShane during the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Contributions

L. Pusztai and F. Andre researched data for the article and wrote the article. All authors contributed ideas to this manuscript, made substantial contributions to the discussion of content, and reviewed and edited the manuscript before submission and following peer review revisions of the article.

Corresponding author

Correspondence to Lajos Pusztai.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pusztai, L., Hatzis, C. & Andre, F. Reproducibility of research and preclinical validation: problems and solutions. Nat Rev Clin Oncol 10, 720–724 (2013). https://doi.org/10.1038/nrclinonc.2013.171

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.171

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research